Artrya (ASX: AYA) signs first partnership with US hospital – The Market Herald

• Artrya Diagnostic Company (AYA) based on artificial intelligence signs first clinical partnership at US hospital with Huntsville Heart Center in Alabama
• The study will be conducted by Heart Center Research, a division of the Huntsville Heart Center to determine the effectiveness of Artrya technology
• The study will use Artrya’s Salix Coronary Anatomy technology to report a unique combination of coronary heart disease biomarkers, including high-risk plaque components
• Arthria also announced that the CEO from 2006 to 2012 of the American College of Cardiology in the United States, Dr. John Levin, has joined his clinical advisory board.
• Arthra ends the day in gray with shares of 70 cents

Artrya (AYA), an artificial intelligence-based diagnostic imaging company, has signed the first clinical partnership in U.S. hospitals with Huntsville Heart Center in Alabama.

The study will be conducted by Heart Center Research, a division of the Huntsville Heart Center, to determine effectiveness Artery Technology.

Research will use Artrya’s Salix Coronary Anatomy technology reports a unique combination of biomarkers of coronary heart disease, including high-risk plaque components.

“This is the company’s first clinical partnership in the United States, and we are pleased that such a respected cardiac center has joined our mission to better identify the world’s leading killer – heart disease.” Commented by Jory Tremblay and Ted Schwab, co-CEO of Artrya USA.

“This clinical trial should be completed by October this year and provide verification of the technology and pave the way for its commercial use in the United States.”

Artrya also announced that the CEO from 2006 to 2012 of the American College of Cardiology in the United States, Dr. John Levin, has joined its Clinical Advisory Board.

Arthra ended the day in gray with shares of 70 cents.